Zach is a biotech investor with PhD training in Biochemistry and Molecular Biology. In real life, he is a scientific writer specializing in continuing medical education. He hopes to provide a crucial piece of total due diligence as well as interesting insight into clinical findings that may impact readers' portfolios and lives.
I'm a small business owner and investor. Previously, I was an intelligence officer and defense consultant with six years of experience in conflict zones.
I use a bimodal portfolio, applying strong defense and offense at the same time. US treasuries, precious metals, and short sales comprise more than 50%. I stake the rest in high payout opportunities, including deep value, distressed debt, special situations, and turnarounds.
Wall Street Breakfast, Seeking Alpha's flagship daily business news summary, is a one-page summary that gives you a rapid overview of the day's key financial news. It's designed for easy readability on the site or by email (including on mobile devices), and is published before 7:00 AM ET every market day.
Wall Street Breakfast readership of over 900,000 includes many from the investment-banking and fund-management industries.
Sign up here to receive the Wall Street Breakfast in your inbox every business day: http://seekingalpha.com/account/email_preferences
Former broker, now an independent analyst/writer on Seeking Alpha and founder and editor of the Growth Stock Forum. Focusing on small-cap, mid-cap and biotech stocks. Looking for substantial sales and earnings growth potential and seeking the best risk-adjusted returns from my stock selection. Taking advantage of medium to long-term momentum.
My articles represent my personal opinion and analysis and should not be regarded as investment advice in any way. Readers and subscribers should do their own due diligence and/or consult their financial advisor before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal.
Exclusive research: http://seekingalpha.com/author/oneil-trader/research
2014 Magna Cum Laude graduate of Ohio Wesleyan University. Pursuing a career in investment management. Passion for value-oriented equity analysis. Specific interest in event-driven investing including spin offs, turnarounds, bankruptcies and M&A opportunities.
Peter Geschek is a freelance writer, investor and the publisher of www.medfrontiers.com website. This is a site for medical innovation news and clinical trials news. Short, concise, important information about the latest is biotech and pharmaceuticals.
Bay Area Biotech is a group of self-organized life science graduate/medical/business students and postdoctoral scholars who are interested in utilizing our scientific training to evaluate biotechnologies and identify investment opportunities. Opinions published here are those of the authors.
Awarded a 2015 "Top 50 Financial Blogger" by TipRanks.com
- Ranked #44 out of 4,408 bloggers (#106 out of 8,174 overall experts) as of 8/18/15
- Follow my ongoing coverage on TerraVia (TVIA): http://seekingalpha.com/articles?filters=tvia,kevin-quon
Seeking Alpha's transcripts team is responsible for the development of all of our transcript-related projects. We currently publish thousands of quarterly earnings calls per quarter on our site and are continuing to grow and expand our coverage.
The purpose of this profile is to allow us to share with our readers new transcript-related developments.
SA Transcripts Team
I am an independent equity research analyst and consultant. I focus on finding small-cap biotech stocks where I believe there is favorable risk / reward because of misinformation, lack of information, or a potential fundamental turnaround. I provide detail analysis for investors and investor relations companies. I also provide due diligence and advisory services to companies. Some names I write on I invest in personally and will disclose my position. Names that have hired me to provide due diligence or advisory services I will disclose a business relationship. I previously worked for Zacks Investment Research from 2003 to 2015 as a Senior Biotechnology Analyst. Prior to Zacks, I spent 1999 to 2002 managing money with Eastover Capital in Charlotte, NC where I focused on large-cap equities, specializing in healthcare, energy, and technology. Prior to joining Eastover, I worked as a research scientist for TechLab, Inc., a biotechnology company focused on developing diagnostic kits and vaccines for infectious diseases, between 1995 and 1998. I also spent a year working at the Fralin Biotechnology Center, and a year working for a cancer researcher while at Virginia Tech. I have a B.S. in Biochemistry from Virginia Tech, with a B.A in Chemistry and a minor in Math. I have a M.B.A. in Finance, with a concentration in Securities Analysis, from Wake Forest University. I hold the Chartered Financial Analyst (CFA) designation.
I am business graduate with a professional certification in F&A. I have been associated with the academic field, teaching both short and long courses on Finance and Accounting but my passion is following and writing about good investments.
I am a physician and vitamin D expert. I am a graduate of the University of North Carolina School of Medicine. In my 35 year career in medicine, I have practiced emergency medicine, general practice and psychiatry.
In 2003, I established the Vitamin D Council, a non-profit dedicated to educating the public and health professionals about vitamin D. I frequently speak about vitamin D and have spoken at the annual meeting of the American Association for the Advancement of Science. I recently served as a "visiting professor" for Marshall University School of Medicine's 25th Annual Research Day.
I have been studying, writing and lecturing about vitamin D for more than 12 years. The Vitamin D Council's website gets over 2.5 million users per year. If you Google my name, "John Cannell", you will get over 60,000 hits, almost all about vitamin D. If you search for "Cannell JJ" on Google Scholar, you will see I have written more than a dozen peer-reviewed scientific articles about vitamin D. Three of my scientific articles (two about influenza and vitamin D and one about autism and vitamin D) are the most cited articles in the history of their respective journals.
Strategic investor/researcher with a primary focus in high percentage gain poised long equity investments. My research areas include the biotech/pharmaceutical sector, precious metals markets, short equities and natural resources.
I am a lawyer and assistant professor living in New York. My work focuses on the intersection of energy policy and the economic feasibility of energy pathways. From a financial perspective I cover a variety of energy companies ranging from renewable energy to fossil fuels. In addition to Seeking Alpha, my articles on renewable energy have been published by media sites including US News & World Report, Newsweek, The Huffington Post, and IFL Science.
While I discuss legal issues relating to these companies on occasion, my articles do not provide legal advice and nothing that I write on Seeking Alpha should be considered as such.
An anonymous contributor who would like to share some of his views. My choice for the pseudonym "Junius" has been inspired by the British political writer in the 18th century who wrote a series of letters promoting individual freedom and liberty; and whose identity has been a source of mystery ever since.
My background is in economics and I always look at how macroeconomic fundamentals affect a given company.
I have an interest in value growth stocks, and options trading. In particular, I enjoy looking at foreign stocks. Although I trade mainly stocks and stock derivatives, I do sometimes trade other financial instruments whenever I believe an opportunity arises.
CJ's goal is to bring institutional quality investment analysis to the pubic.
CJ likes the following things: investing, light exercises, and the philosophy of Haimchinkel Malintz Anaynikal.
CJ dislikes the following things: vegetables, strenuous exercise, paper cuts, and the opinions of sell side analysts.
I have been an active investor for almost 20 years. My main focus is on high-yield stocks, particularly MLPs, and high-growth oil companies in the Eagle Ford shale. I have a portion of my portfolio allocated to short-term trading, with a focus on over-reactions to company news and directional plays on VIX-based ETFs. I am happy to answer just about any question sent my way, especially from those new to the stock market.
I am a young professional with a passion for finance and investing. I am not a professional investor, but over the years I have constantly searched for fundamental long and short ideas for my individual portfolio. I have an undergraduate degree in both finance and accounting and an MBA in accounting. I am a CPA and am currently studying for the CFA charter.
Investor with more than 5 years experience trading commodities, gold and silver miners, exploration companies, oil and gas, platinum and other hard assets.
The investment style is part contrarian/value and I actively seek investments in distressed sectors.
I am an active investor in IP-centric investments for 5 years. I specialize in high risk / high reward situations both public and private. It is important for investors to plan for all outcomes as the litigation surrounding the IP investment takes many twists and turns. Extracting profits and limiting exposure are the keys to success.
I hope to provide information and strategies, which both expert and novice IP investors can profit from.
Follow me on twitter for the latest updates in the IP space:
Tim Iacono is the founder of the investment website 'Iacono Research', a subscription service providing market commentary and investment advisory services specializing in natural resources.
He also writes a financial blog known as 'The Mess That Greenspan Made', a sometimes irreverent look at the many and varied after-effects of the Greenspan term at the Federal Reserve.
Use the links below to visit Tim's website/blog.
I am a retired global analyst, currently busy in investing and writing articles about stocks at several investing publications and websites. I have also developed strategies for creating winning portfolios according to specific formulas.
In January 2015, I was ranked among the world’s top 10 financial bloggers according to TipRanks, which holds financial experts accountable for their recommendations by disclosing their stock ratings since 2009:
Acting Man has been named after the title of the first chapter of Ludwig von Mises' book "Human Action" - the best treatise on economics ever written. The blog's main author is Pater Tenebrarum, an independent analyst who has been involved with financial markets for 34 years and is writing economic and market analyses for independent research organizations and a European hedge fund consultancy. Acting Man presents articles on the markets and the economy, a mixture of commentary on current events as well as economic theory and history, mainly from an Austrian School of Economics viewpoint. As more authors have joined the site, we have begun to broaden our palette a bit, but our orientation remains the same: pro-free market, anti-state, pro peace.
I spent many years working in various analytic jobs and trading on Wall Street. For nine of those years, I traded junk bonds for a large bank. I have an MBA from the University of Chicago, with a concentration in accounting and finance. Currently I co-manage a precious metals and mining stock investment fund in Denver. My goal is to help people understand and analyze what is really going on in our financial system and economy.
Bookmark QTR's new blog, where exclusive (and always FREE) content will be available: http://www.quoththeravenresearch.com
Visit QTR and check out trading ideas, commentary, and me arguing with idiots on Twitter: http://www.twitter.com/quoththeravensa
QTR's ARTICLES ARE BOUND BY SA'S CONTRIBUTOR POLICY IN ADDITION TO THIS ENTIRE LENGTHY, YET EXTREMELY PERTINENT ADD ON DISCLOSURE, WHICH SERVES AS BOTH A STANDALONE DISCLOSURE AND AN AMENDMENT TO ANY AND ALL DISCLOSURES ALREADY PRESIDING OVER SEEKING ALPHA:
Quoth the Raven's ("QTR") articles are the sole product of QTR and his personal, individual opinions. These articles are not associated with, in any way, the opinions, strategies, or works of QTR's employer, associates, or entities in any way otherwise related to QTR.
(i.e. This are solely my personal thoughts and opinions)
You agree that by reading Quoth the Raven's articles, you are acting at your OWN RISK. In NO EVENT should QTR be liable for any direct or indirect trading losses caused by any information contained in QTR's articles, StockTalks, or other internet-based dissemination methods. Information in QTR's articles are not an offer to sell or a solicitation of an offer to buy any security, nor shall any security be offered or sold to any person, in any jurisdiction in which such offer would be unlawful under the securities laws of such jurisdiction. QTR is not suggesting the transacting of any financial instruments and QTR suggests consulting your personal financial adviser with regards to any such transactions.
QTR makes no representations, and specifically disclaims all warranties, express, implied, or statutory, regarding the accuracy, timeliness, or completeness of any material contained in this site. Again, you should seek the advice of your personal financial adviser or a security professional regarding your stock transactions.
QTR does not, in any way, guarantee that he is providing all of the information that may be available on any topic written. QTR recommends, again, that you do your own due diligence and consult a registered financial adviser before buying or selling any security.
QTR most always holds a position in any of the securities profiled in his pieces and he constructs his SA disclosures in accordance with SA's Contributor Policy, to the best of his knowledge in order to maintain transparency and also to uphold and respect pertinent securities laws. QTR may or may not report when a position is initiated or covered. Each investor must make that decision based on his/her judgment of the market.
I am not a stockbroker or financial adviser. I am a casual investor making casual observations for the purpose of discussion and open communication and analysis of companies and stocks. All articles are my opinion only and are not suggestions to buy or sell any equity, bond, option or other financial instrument. QTR may have long or short positions in any tickers mentioned at any time and reserves the right to open, close, or modify positions at all time without notice. My conclusions are the result of my personal due diligence and have been wrong in the past. There are tons of unqualified people out there offering up financial advice and its your responsibility to sort through the BS. You don't hit the button to fill my orders and I don't hit yours, so no whining or praising over stocks covered by me.
Follow QTR on Twitter: https://twitter.com/QuoththeRavenSA
View QTR's Stock Picking Performance for every article at TipRanks:
John A. Sarkett is the designer of Option Wizard® software (http://option-wizard.com), the latest iteration of which is Option Wizard® Simplified Options Strategy (SOS) Backtester, which was featured in the July 2011 TASC. He writes frequently on financial topics for publications such as SFO and Technical Analysis of Stocks and Commodities.
Additionally, he is:
Author of best-selling Extraordinary Comebacks: 201 Inspiring Stories of Courage, Triumph, and Success and its follow-up volume: Extraordinary Comebacks 2. He also wrote the original Option Wizard® Trading Method (1998, updated 2008), as well as Option Wizards®: real life success stories from the financial markets (2012).
Publisher of the new AIN'T JUST BLUES IT'S SHOWTIME: Hard times, heartache, and glory along Blues Highway, and more recently, Stephen Széchenyi And The Awakening Of Hungarian Nationalism, 1791-1841. See more of his titles at http://sarkett.com.
Class President of the National University of Singapore MBA Program and former FX trader at CIBC (NYSE: CM). Sean holds a Bachelor of Commerce Degree with a Major in Finance and Minor in Economics from the Sauder School of Business at the University of British Columbia.